Last reviewed · How we verify

Benidipine Hydrochloride — Competitive Intelligence Brief

Benidipine Hydrochloride (Benidipine Hydrochloride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker. Area: Cardiovascular.

phase 2 Calcium channel blocker L-type calcium channels Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Benidipine Hydrochloride (Benidipine Hydrochloride) — The Society of Prevention and Awareness of Cardiovascular Diseases. Calcium channel blocker

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Benidipine Hydrochloride TARGET Benidipine Hydrochloride The Society of Prevention and Awareness of Cardiovascular Diseases phase 2 Calcium channel blocker L-type calcium channels
Losartan and amlodipine and hydrochlorothiazide Losartan and amlodipine and hydrochlorothiazide Hotel Dieu de France Hospital marketed Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic) Angiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter
Calcium Channel Blockers, ACE-Inhibitor Calcium Channel Blockers, ACE-Inhibitor University of Aarhus marketed Combination antihypertensive (calcium channel blocker + ACE inhibitor) L-type calcium channels; Angiotensin-converting enzyme (ACE)
losartan/amlodpine losartan/amlodpine University of Pavia marketed Angiotensin II receptor blocker (ARB) / Calcium channel blocker (CCB) Angiotensin II receptors (AT1) and L-type calcium channels
Perindopril plus Amlodipine Perindopril plus Amlodipine University of Abuja marketed ACE inhibitor + Calcium channel blocker combination ACE (angiotensin-converting enzyme) and L-type calcium channels
Phase B: Triplixam / Elestar HCT Phase B: Triplixam / Elestar HCT National Institute of Cardiology, Warsaw, Poland marketed Fixed-dose combination antihypertensive (calcium channel blocker + ARB + thiazide diuretic) L-type calcium channels, angiotensin II type 1 receptor (AT1R), sodium-chloride cotransporter
Perindopril + amlodipine + if necessary, hydrochlorothiazide Perindopril + amlodipine + if necessary, hydrochlorothiazide Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company marketed ACE inhibitor + calcium channel blocker + thiazide diuretic combination Angiotensin-converting enzyme (ACE), L-type calcium channels, sodium-chloride cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker class)

  1. Shenzhen Ausa Pharmed Co.,Ltd · 2 drugs in this class
  2. Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
  3. Ain Shams University · 1 drug in this class
  4. Bioprojet · 1 drug in this class
  5. Bristol-Myers Squibb · 1 drug in this class
  6. GlaxoSmithKline · 1 drug in this class
  7. Handok Inc. · 1 drug in this class
  8. Hasten Biopharmaceutical Co., Ltd. · 1 drug in this class
  9. Hospital de Clinicas de Porto Alegre · 1 drug in this class
  10. Laboratorios Richmond S.A.C.I.F. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Benidipine Hydrochloride — Competitive Intelligence Brief. https://druglandscape.com/ci/benidipine-hydrochloride. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: